Presenting results from the REDEFINE 1 and REDEFINE 2 studies at the American Diabetes Association (ADA) congress in Chicago, Novo Nordisk pointed to a good tolerability profile for CagriSema and ...

Danish drugmaker Novo Nordisk has released fresh clinical data on two of its lead investigational assets, seeking to bolster ...

By Sanchayaita Roy and Sukriti Gupta (Reuters) -European shares were mixed in choppy trading on Monday, amid escalating ...

Novo Nordisk dropped a pile of scientific data on three new experimental weight-loss drugs, including an oral one, showing ...

The combination of once-weekly cagrilintide 2.4 mg and semaglutide 2.4 mg conferred greater weight loss at 68 weeks compared ...

Patients who took a lower dose lost more weight on average. Read more at straitstimes.com. Read more at straitstimes.com.

The Financial Times, reported but not verified by Reuters, covers British Airways and Singapore Airlines canceling flights to ...

In addition, the company reported a 21% mean weight loss in a higher dose cohort of the 7.2 mg formulation of Wegovy ...

CHICAGO -- Adding investigational cagrilintide to a GLP-1 receptor agonist increased weight loss in adults with obesity with ...

Phase 3 REDEFINE 1 trial found that treatment with CagriSema led to a 22.7% weight loss at 68 weeks among patients who adhered to the treatment, compared ...

Trials of a new drug for obesity and type 2 diabetes have seen patients lose 15pc of their body weight and return their blood ...